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ChIP-seq chromatin immunoprecipitation with massively parallel DNA
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CpG a DNA methylation site where a cytosine is followed by a
guanine
CRC colorectal cancer
CRPC castration-resistant prostate cancers
DEG differentially expressed genes
d a matrix of distances between genes (g) and peaks (p)
DNA deoxyribonucleic acid
EM expectation maximisation
FoxA1 forkhead box protein A1
g an index for a gene
GBM glioblastoma multiforme brain cancer
GO Gene Ontology
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IBD identical by descent
IPAVS Integrated Pathway Resources, Analysis and Visualization
System
JASPAR name of the TF BS consensus sequence database
KEGG Kyoto Encyclopedia of Genes and Genomes (database)
LOH loss of heterozygosity
MACS Model-based Analysis for ChIP-Seq
MEME Multiple EM for Motif Elicitation
MM mismatch probe
mRNA messenger ribonucleic acid
n number of nucleotide positions in a DNA binding site motif
p an index for a BS peak
PM perfect match probe
RNA ribonucleic acid
Sh/l Highest/lowest possible alignment score for the given motif
siRNA small interfering ribonucleic acid
SNP single nucleotide polymorphism
TCGA The Cancer Genome Atlas (data provider)
TF transcription factor
w a vector of read alignment overlap enrichments between the
case and the control samples at peaks p
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nen V, Karinen S, Nousiainen K, Lahesmaa-Korpinen A-M,
Miettinen M, Saarinen L, Kohonen P, Wu J, Westermarck J,
Hautaniemi S. (2010). Large-scale data integration framework
provides a comprehensive view on glioblastoma multiforme.
Genome Medicine, 2(9):65.
Publication III Laakso M, Hautaniemi S. (2010). Integrative platform to
translate gene sets to networks. Bioinformatics, 26:1802–1803.
∗ equal contribution to the work
The author’s main contributions to the papers are:
Publication I The development of the algorithm, visualisation and the data
analysis, execution of the data analysis, probabilistic characterisation of the
algorithm, drafting of the article.
Publication II The functional design of the Anduril framework together with
KO, contribution to the development of over 60 Anduril components, anal-
ysis of the gene expression and survival data together with EV, revision of
the article critically for important intellectual content.
Publication III The design of the database structure and the related accession
methods, application of these methods to the analysis of genes with a
survival association in glioblastoma, drafting of the article.
v
Related publication and contributions
The following publication relates to this thesis but has not been included in the
official publications. Faculty of Medicine recommends that at most half of the
original publications of each thesis are shared in other theses. This unshared
publication will be reserved for the first author planning to use it in his thesis.
RelPublication Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, Rannikko
A, Sankila A, Turunen JP, Lundin M, Konsti J, Vesterinen T,
Nordling S, Kallioniemi O, Hautaniemi S, Jänne OJ. (2011).
Dual role of FoxA1 in androgen receptor binding to chromatin,
androgen signalling and prostate cancer. The EMBO Journal,
30(19):3962–3976.
The author’s main contributions to the paper are:
RelPublication Development of the data analysis pipeline for the gene expres-
sion microarrays and the transcription factor binding sites, revision of the
article regarding to the data analysis.
vi
Abstract
The genetic alterations of cancer cells vary between individuals
and during the progression of the disease. The advances in measure-
ment techniques have enabled genome-scale profiling of mutations,
transcription, and DNA methylation. These methods can be used to
address the complexity of the disease but also raise an acute demand
for the analysis of the high dimensional data sets produced.
An integrative and scalable computational infrastructure is ad-
vantageous in cancer research. First, a multitude of programs and
analytic steps are needed when integrating various measurement types.
An efficient execution and management of such projects saves time
and reduces the probability of mistakes. Second, new information
and methods can be utilised with a minor effort of re-executing the
workflow. Third, a formal description of the program interfaces and
the workflows aids collaboration, testing, and reuse of the work done.
Fourth, the number of samples available is often small in comparison
with the unknown variables, such as possibly affected genes, of interest.
The interpretation of new measurements in the context of existing
information may limit the number of false positives when sensitive
methods are needed.
We have introduced new computational methods for the data
integration and for the management of large and heterogeneous data
sets. The suitability of the methods has been demonstrated with
four cancer studies covering a wide spectrum of data from population
genetics to the details of the transcriptional regulation of proteins,
such as androgen receptor and forkhead box protein A1. The repeat-
able workflows established for these colorectal cancer, glioblastoma,
and prostate cancer studies have been used to maintain up-to-date
registries of results for follow-up studies.
Tiivistelmä
Syöpäsolujen geneettiset muutokset vaihtelevat potilaittain ja
taudin edetessä. Mittausmenetelmien kehittyminen on mahdollis-
tanut mutaatioiden, transkription, sekä DNA-metylaation genomin-
laajuisen kartoittamisen. Genomin kattavia menetelmiä voidaan käyt-
tää monitekijäisten syöpäsairauksien tutkimuksessa, mutta niiden
myötä on syntynyt tarve moniulotteisen tiedon tarkasteluun sovel-
tuville menetelmille.
Joitakin syöpätutkimukseen liittyviä haasteita voidaan ratkaista
yhdistävällä ja skaalautuvalla laskennallisella infrastruktuurilla. En-
simmäiseksi, erilaisten mittausten yhdistämiseen tarvitaan useita
sovelluksia ja tarkasteluvaiheita. Kokonaisuuden automatisoitu suori-
tus ja hallinta säästävät aikaa ja pienentävät virheiden mahdolli-
suutta. Toiseksi, uutta tietoa ja menetelmiä päästään hyödyntämään
pienellä vaivalla uudelleen suorittamalla työnkulku. Kolmanneksi,
ohjelmistorajapintojen ja työnkulkujen määrämuotoinen kuvaus helpot-
tavat yhteistyötä, testausta ja tehdyn työn uudelleenkäyttöä. Neljän-
neksi, saatavilla olevien näytteiden lukumäärä on usein pieni verrat-
tuna kiinnostuksen kohteena oleviin tuntemattomiin muuttujiin, kuten
mahdollisesti vioittuneisiin geeneihin. Uusien mittausten tulkinta ole-
massa olevan tiedon yhteydessä saattaa vähentää väärien positiivisten
määrää kun tarvitaan herkkiä menetelmiä.
Olemme esitelleet uusia laskennallisia menetelmiä tiedon yhdis-
telyyn, sekä laajojen ja vaihtelevan muotoisten aineistojen käsitte-
lyyn. Menetelmien käyttökelpoisuutta olemme havainnollistaneet
soveltamalla niitä neljässä syöpätutkimuksessa, jotka liittyvät paksun-
suolen syöpään, glioblastoomaan ja eturauhassyöpään. Tutkimusten
aihealueet kattavat kirjon populaatiogenetiikasta transkriptiotekijöi-
den, kuten androgeenireseptorin ja FoxA1:n toiminnan, yksityiskohtiin.
Tutkimusten puitteissa toistettavaan muotoon rakennetut työnkulut
ovat tuloksineen tarjonneet ajantasaisen tietolähteen pohjaksi jatko-
tutkimuksille.
1 Introduction
Cancer is characterised by the cells that have lost their growth controlling ability
as a consequence of a set of genetic or epigenetic defects accumulated to their
genome (Vogelstein and Kinzler, 2004; Martini et al., 2011). The pattern of
defects varies between and within individual tumours and during their progres-
sion (Dancey et al., 2012; Gerlinger et al., 2012). The malignant growth and the
invasive nature of the cancer cells may disturb the normal body function. Indeed,
7.6 million annual cancer caused deaths are reported world wide (WHO, 2011).
In the following text, the focus is on colorectal cancer, glioblastoma, and prostate
cancer, which have been studied in Publications I–III and in RelPublication.
Molecular measurement techniques have evolved rapidly over the last decades
enabling genome-scale analysis of the DNA sequences and gene expressions (Chen
et al., 2012). The advanced understanding of human genome and genetic variation
between individuals has improved the resolution of the assays as more specific
probes can be produced and denser maps of markers have become available (Frazer
et al., 2007; Van der Ploeg, 2009; Levsky and Singer, 2003). At the same time,
throughput of measurements has increased due a higher level of parallelisation
and multiplexing. The invention of microarrays and the development of new
stainings and sequence labels have enabled simultaneous observation of many
biological variables (Hoheisel, 2006; Levsky and Singer, 2003). The computational
analysis of the produced data sets, especially the integration between platforms
and experiments, has become a challenge (Wilkes et al., 2007). Although new
methods have been introduced for the sample collection and preparation, the
reproducibility and the accuracy of the biomedical measurements can be improved
still (Wilkes et al., 2007; Van der Ploeg, 2009).
The number of biological databases and biomedical articles is increasing and
they provide a rich source of information that may facilitate functional and
causal interpretation of the observations. The dimensions of data produced in
genome-scale studies are challenging for the traditional statistics. The number of
unknown variables (genes, genomic loci) is vast compared to the number of cases
(samples) (Houlston and Peto, 2004; Easton et al., 2007). Existing information
regarding the variables can be used to compensate the related uncertainty and
some of the challenges can be solved by using biological databases during the
data analysis. An automated version of such analysis enables rapid adjustments
of the results as new information becomes available.
External data sources can be useful when selecting candidates for the validation,
but an integrative system that covers them may become fragile and hard to
maintain. Each external resource adds new complexity to the system as their
interfaces and content tend to change in time. The latest information cannot be
captured without revising the resources periodically, which means that one has
to maintain compatibility between the systems. Another technical challenge lays
in the heterogeneity of the biomedical resources. For instance, different assays
have been used to measure patient genotype, somatic mutations in tumours, gene
expression, and DNA methylation. Related knowledge is represented in terms
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of frequent alterations in certain tumours, models describing the interactions
between some bioentities, and functional annotations assigned to the genomic
loci. Although new standards have been established for biomedical data (Turenne,
2011), the representation and the accession method of all this information typically
varies according to the providing source.
A computational infrastructure can help in repeating and maintaining analyses
that are comprised of steps implemented in various computer programs (Almeida,
2010; Evans, 2011; Podpečan et al., 2011). Workflow engines are software frame-
works specialised in the management and execution of computational processes
consisting of tasks and the dependencies between them. A workflow engine
based computational infrastructure can be used for the simultaneous analysis of
multiple data sets of various kinds. We demonstrated the advantages of such an
approach by analysing survival associations in The Cancer Genome Atlas (TCGA)
glioblastoma multiforme (GBM) data set. TCGA is established by the National
Cancer Institute and the National Human Genome Research Institute (at the
United States of America) in order to improve the molecular understanding of
cancer by providing a shared repository of data. GBM data set consisted of
samples of 338 patients and it was among the widest genome-wide cancer data
sets available in 2009 (McLendon et al., 2008).
An efficient analysis of the data sets is a prelude to the functional and causal
interpretation of the genome-scale data. The existing pipelines of case-control
studies produce distribution profiles and literature annotations of individual
entities over the sample sets. The results are typically summarised in terms of
pathway impacts (Tarca et al., 2009) and enrichments of certain annotations
among them (Subramanian et al., 2005; Ovaska et al., 2008). New methods are
needed for the automated pathway integration that could address the crosstalk
between the pathways (Bauer-Mehren et al., 2009). We directed our efforts to
compare pathways and result sets by establishing a database called Moksiskaan
that combines information about relationships between entities such as genes,
proteins, diseases, drugs, pathways, cellular components, and biological functions.
This database enabled a construction of connectivity graphs between the entities
of interest, which aid the interpretation (Liikanen et al., 2011; Heinonen et al.,
2011; Louhimo et al., 2012).
The extraction of the relevant set of relationships is one of the key challenges
when a large pool of heterogeneous interaction data is used in a specific bio-
logical context. Functional dependencies between the biological entities can be
learned by measuring biological cascades at various levels (Pe’er and Hacohen,
2011). For instance, genome-wide profiles of the transcription factor (TF) bind-
ing sites (BS) can be integrated with the cellular responses in order to identify
the functional targets. The pre-existing information about the DNA binding
motifs of other TFs (Portales-Casamar et al., 2010) is also useful in this con-
text, as we demonstrated in the study of androgen receptor (AR) in prostate
cancer (RelPublication).
2
2 Review of the literature
This section provides a summary and the key references of the published knowl-
edge regarding the production and analysis of genome-wide measurements of
glioblastoma (Publication II; Publication III), colorectal (Publication I), and
prostate cancers (RelPublication).
2.1 Genome-scale measurements
The release of the human reference genome enabled studies that relied on the
genomic loci of the sequence fragments (Lander et al., 2001). The reference is also
being used to estimate how many times certain fragments occur at the genome
and to identify unique fragments (Gräf et al., 2007). The reference itself does
not represent a real genome but it has been constructed by combining samples of
different individuals (Lander et al., 2001). More importantly, a fixed reference is
not able to capture the variations seen between individuals, not to mention the
defects seen in cancer cells.
Still, once fixed the reference provided the means by which these variations can
be described and, indeed, massive projects have been established for this purpose.
HapMap (Frazer et al., 2007) collects data about the variants and their segregation
in humans. Catalogue of Somatic Mutations in Cancer (COSMIC) (Forbes et al.,
2008) is a cancer project that focuses on somatic variants present in tumours.
The joint information about the reference and the common variants has been used
to discover short but still unique sequence fragments of the genome. A variety of
high-throughput measurement techniques have emerged from the opportunity to
first measure these sequences from the sample material and then to map these
signals to their positions in the genome.
Genome-scale studies of DNA and its transcriptional regulation are based on
the measurements aiming for a complete or at least unrestricted set of targets.
An important aspect of these studies is that the number of null hypotheses is
typically high. The same hypothesis (such as ‘the expression of this gene does not
differ between the case and control samples’) may be applied to tens of thousands
of genes. Large sample sets may be needed in order to produce reliable results
while keeping the number of false positives low. Multiple hypothesis corrections,
such as Bonferroni correction and false discovery rate (FDR) (Benjamini and
Hochberg, 1995), can be used to estimate overall reliability of the results.
The total length of a human genome is over 3.1 · 109 base pairs (bp) (Flicek
et al., 2011), which enables an enormous potential for variation. HapMap describes
over 3.1 · 106 single nucleotide polymorphisms (SNP) that are estimated to cover
25%–35% of the SNP variations among the studied four populations of African,
Asian, and European ancestry. The genome-scale studies focusing on phenotype-
genotype relationships are typically faced with challenges of low numbers of
samples versus the dimensions and the variability of the genome. Not all loci are
equally susceptible for alterations (Martini et al., 2011).
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2.1.1 Single nucleotide polymorphism microarrays
The contemporary SNP-microarrays enable simultaneous genotyping of hun-
dreds of thousands of SNPs (Kathiresan et al., 2009; LaFramboise, 2009). The
exact SNPs and the expected alleles are defined in advance during the manu-
facturing of the microarray, which is in contrast to the less biased sequencing
techniques discussed in Section 2.1.4. SNP-microarrays can be used to measure
genotypes of hundreds of thousands up to a million biallelic SNPs (LaFramboise,
2009). The SNPs are distributed non-uniformly but relatively densely across the
genome (Madsen et al., 2007).
SNP-microarrays, like other complementary DNA hybridisation microarrays,
are based on short single stranded DNA fragments called probes that are fixed on
the solid surface of the array. Probes have been designed so that they represent
the complement strand for the sequence around the target sequence and are
unique to that. The selection of unique probes has biased commercial arrays
towards SNPs on non-coding sequences, which limits their capability to detect
gene variants (Nicolae et al., 2006). The information content of the probes depends
on how independently their alleles segregate in respect to the neighbouring alleles.
Nicolae et al. (2006) demonstrated that about 40% of the SNPs selected for the
commercial Affymetrix array were highly dependent on their neighbour, thus the
practical resolution of the array is not necessarily as high as assumed based on the
number of SNPs covered. The chosen probes are clustered to distinguishable spots
consisting of clones of an identical sequence and each of these spots represents an
allele of a SNP. Typical commercial arrays support biallelic SNPs, which means
that they provide at least two probe sequences for each SNP, both having a
different nucleotide at the site of the SNP.
In Affymetrix GeneChip R© Human Mapping 100K Set, used in Publication I,
there are 40 different 25bp long probe sequences for each SNPs. Half of the probes
are so called mismatch probes (MM) having a middle nucleotide which does not
match either of the two alleles in the reference genome. The purpose of these
probes is to reflect the level of non-specific cross hybridisation, but their necessity
has been of debate, especially in the context of gene expression microarrays as
will be discussed in Section 2.1.2 (LaFramboise, 2009). The other half of the
probes, the perfect match probes (PM), represent exact alignments for the allele
specific sequences but vary in their positioning in respect to the SNP. Figure 1
illustrates a hypothetical quartet of probes and a perfect alignment of one allele.
Genotypes of the sample DNA are predicted based on its hybridisation with
the microarray probes. Before the hybridisation, sample DNA is enzymatically
fragmented to match the array probes. The digestion enzymes are sequence
specific and thus the SNPs have to be selected so that the enzymes can produce
suitable fragments for the probes (Mao et al., 2007). Next, the fragments are
labelled with a fluorescent marker so that they can be detected on the microarray
once hybridised. The labelled fragments are placed on the microarray where they
can bind with the probes, and the excess material is washed away. The results of







































































































































Figure 1: A fluorescent labelled sample oligonucleotide has hybridised with the PM of
the C allele, which belongs to a quartet designed for a C/T SNP. Each probe belongs
to a spot consisting of its clones. The intensities of these spots are determined from
the scanned image of the array. The image has been edited from Laakso (2007).
the fluorescent marker. The scanning produces a figure of the array surface, which
is then analysed computationally. Spots of the probe clusters are detected and
the signal intensity of each cluster is estimated for the included pixels.
Probe cluster intensities are compared between the clusters representing
different alleles of the same SNP, and the relative intensities are interpreted
as genotypes. A heterozygous sample containing one copy of alleles A and a
produces a balanced signal for the corresponding spots. A homozygous sample
(AA) produces a higher signal for A, whereas the signal of a remains at the level
of the background produced by the cross hybridisation between the partially
matching probe and sample DNA. The signal intensities, especially when analysed
together with the neighbouring SNPs, can be used to estimate local amplifications
of the genome (corresponding genotypes such as AAa and aaaa) (LaFramboise,
2009).
2.1.2 Gene expression microarrays
Gene expression microarrays are used to measure messenger ribonucleic acid
(mRNA) levels of the cells. The technology of these microarrays resembles that
of the SNP-microarrays, except that the probe sequences have been selected from
the mRNA sequences of the genes. Several short probe sequences are typically
used for each targeted gene. The sample preparation is also different since the
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original RNA is first converted to DNA using a reverse transcriptase before it is
labelled and hybridised.
Quantitative analysis of the gene expression is more sensitive for the prepro-
cessing of the image data than the discrete classification of the genotype calls. The
intensity scale of an individual microarray is a result of the sample concentration,
volume and the hybridisation conditions providing relative information about the
probes within the array (Quackenbush et al., 2001). Normalisations are used to
adjust these scales for a better comparability between the arrays by reducing the
effects of non-biological origin (Bolstad et al., 2003).
In RelPublication, we have used quantile normalisation that assumes a common
overall distribution of probe intensities for each array, although the signals of
individual genes may vary (Bolstad et al., 2003; LaFramboise, 2009). The values of
each sample are sorted independently, and then the value at each sorted position
is replaced with the mean of the values at the same position on all arrays. Figure 2
illustrates the effects of the normalisation in RelPublication. Each normalised
sample provides the same set of values and thus the distributions are equal
although the values may belong to different genes. The improved comparability
of the normalised values can be seen in the average distance based hierarchical
clustering that makes a clear distinction between the corresponding replicates
and the other samples. The gene expression values are formed by combining the
values of the probe spots related to the gene. In RelPublication, a median was
used to combine these values.
Some probe and sample fragments are hybridised together although their
sequences are not fully complement to each other. The MM of the Affymetrix
GeneChip R© microarrays are intended for the background correction of this non-
specific hybridisation that contributes to the signals of PM. Alternatively, the
background signal can be estimated from the PM assuming the observed signals
are sums of exponentially distributed signals of the fully compatible sequences and
a normally distributed (with a positive truncation) background signal. Robust
multi-array average is a microarray normalisation method that combines the
PM based background correction with the quantile normalisation (Irizarry et al.,
2003). This method has been used for the pre-normalised glioblastoma data we
obtained from TCGA (Publication II; Publication III).
The general steps of hybridisation, image processing, quality control, nor-
malisation, and the expression comparisons between the samples are common
in gene expression microarray studies, but their actual forms vary between the
projects. As Quackenbush et al. (2001) stated, a common approach may never fit
for all applications and aspects of the research. For this reason, flexible computa-
tional infrastructures are important as they aid the quick construction of suitable
combinations of the methods and the evaluation of different approaches.
Exon arrays are high density gene expression microarrays, which provide
probes for each exon of the gene. The exon specific signals can be used to infer
the relative abundances of the splice variants of the same gene (Gardina et al.,


























































































Figure 2: Signal distributions and the hierarchical clusterings of the gene expression
arrays before (a) and after (b) the quantile normalisation. These Illumina HumanHT-12
v3 Expression BeadChip Kit microarrays were used to measure 5α-Dihydrotestosterone
responses in parental (c) and FoxA1 depleted (a1) LNCaP cells. Control samples have
been labelled with e, and d stands for the treatment. Two replicates (1, 2) have been
used for each condition.
7
2.1.3 Chromatin immunoprecipitation with microarray
Chromatin immunoprecipitation is an antibody based targeted DNA isolation
procedure that is based on the recognition of the DNA attached proteins. The
procedure, when coupled with the determination of the sequences of the isolated
DNA fragments, can be used to estimate the binding sites of the protein of
particular interest. Depending on the antibody, the same procedure can be used
in the studies of transcription factor binding sites, histone modifications, and
RNA polymerase activities. The protocol consists of four steps (Aparicio et al.,
2004):
1. Formaldehyde, for example, is applied to cross-link proteins with the DNA
in its proximity.
2. DNA is fragmented to short sequences in order to enhance the binding site
specificity and to lower the molecular size of the protein-DNA complexes.
3. An antibody is used to selectively isolate DNA fragments attached to the
protein of interest. This step is called immunoprecipitation.
4. The proteins are detached from the DNA.
The sequence of the purified DNA fragments may be determined in various
ways. One option, called ChIP-chip, is to use microarrays for this purpose (Wu
et al., 2006). Special microarrays (DNA tiling arrays) have been developed for
this purpose. These arrays have a high density coverage of the unique sequences
of the genome, and the spot intensities of the hybridized arrays can be interpreted
as quantitative measures of the corresponding fragments in the sample material.
The known sequences of the probes, when aligned against the reference genome,
are used to predict the chromosomal loci of the protein binding sites. A typical
binding site is observed as an increased intensity of the probes, which correspond
to near-by sites in the chromosome. The intensities of the probes are higher
near the exact binding site and decrease towards more distant probes as the
corresponding DNA is more likely cut off from the protein attached part during
the fragmentation.
2.1.4 Massively parallel sequencing
DNA sequencing techniques are evolving quickly, and the conventional comple-
mentary DNA hybridisation microarrays may be often replaced with massively
parallel sequencing assays (Marioni et al., 2008; Park, 2009). An excessive amount
of raw data is typically produced by a sequencing experiment, hence the infor-
mation is more detailed (the composition of the DNA fragments in addition to
their relative concentration) than with the microarrays. Consequently, an efficient
computational infrastructure is needed for the processing and storing purposes.
There is a great interest in using massively parallel DNA sequencing for the
genotyping purposes (Nielsen et al., 2011; Davey et al., 2011). The advantage of
the sequencing techniques is that they are less dependent on the probe design and
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may thus better capture unexpected alleles and variations (Wheeler et al., 2008).
Depending on the DNA preparation protocol, the same data can be used to infer
much more information than the SNPs. For instance, a complete sequence may
reveal chromosomal rearrangements and other mutations (Pareek et al., 2011).
The sequencing methods are prone to errors, and thus a high sequencing coverage
is needed at the variation site in order to obtain enough reads from the two
possible alleles and to distinguish between them and the errors (Nielsen et al.,
2011). Instead of a complete genome, a targeted sequencing of the exons may be
used. By focusing on exons, a higher coverage or a larger set of samples can be
analysed at the price of the complete genomes. The exon sequences have already
been used to identify recessive mutations as variants present in both homologous
chromosomes (Bilgüvar et al., 2010). Importantly, fewer samples are needed if
the variants are determined at the individual level, instead of comparing the case
and control frequencies of the putative chromosome regions found from the SNP
data.
Massively parallel sequencing of the mRNA provides an alternative to the
gene expression microarrays (Marioni et al., 2008). Analogous to the microarrays,
the RNA is first converted to complementary DNA before it is sequenced. The se-
quence data can be used for the detection of alternative splicing as more sequence
fragments are obtained from the more abundant exons. In addition, sequencing
data provides sequence fragments that may overlap the exon boundaries, provid-
ing direct evidence of the splicing. Sequence overlaps that match partially with
two different genes may be used to detect fusion genes caused by chromosome
translocations (Ozsolak and Milos, 2010). The mRNA sequencing can be per-
formed with a small amount of sample material, which enables transcriptional
analysis of individual cells (Tang et al., 2009; Ozsolak and Milos, 2010).
Chromatin immunoprecipitation with massively parallel DNA sequencing
(ChIP-seq) is an assay similar to ChIP-chip, except that the tiling microarrays are
replaced with sequencing of the immunoprecipitated DNA fragments. Sequence
data is converted to binding site coordinates by aligning sequence fragments
against the reference genome. Bindings are predicted at those loci that have a high
local enrichment of overlapping alignments. In practise, the current sequencing
techniques can only measure the ends of the precipitated DNA fragments and this
limits the resolution of the binding site boundaries (Zhang et al., 2008). Technical
details of the data analysis are further discussed in Section 4.3.
ChIP-seq provides typically a better overlap between sample replicates than
ChIP-chip, and the spatial resolution of the binding site predictions is enhanced
as characterised in Park (2009) and Ho et al. (2011). We used tiling arrays in the
beginning of the androgen receptor study, but the approach was replaced with
Illumina’s Solexa sequencer due to higher resolution and improved data quality
of the ChIP-seq technology.
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2.2 Biological pathways
The evolutionary selection has led to organisms with complex chemistry that
can be adjusted based on the environmental factors. The relationships between
cellular molecules and genes can be represented as graphs (Papin et al., 2005;
Aittokallio and Schwikowski, 2006; Pisabarro et al., 2008; Jensen et al., 2009; Pe’er
and Hacohen, 2011; Yosef et al., 2011). Genes, proteins, and other compounds
are vertices and their relationships are represented with edges. The topologies of
these graphs can be used as a basis of the mathematical models explaining the
cell function (Papin et al., 2005; Bauer-Mehren et al., 2009).
The relationships between the molecules representing a certain condition,
such as prostate cancer or response to a certain stimulus, such as hormones
(Figure 3), are often referred to as canonical pathways. The canonical pathways
are not exclusive but they share common entities and connectivities. Importantly,
these pathway descriptions are not complete. They are used to describe the key
elements and their relations, although these elements are not in isolation (Ma’ayan
et al., 2005). The reduction, although helpful in the described context, produces
additional challenges when the interest is in the crosstalk between the canonical
pathways. We use the term fusion pathway for these hypothetical models that
represent relationships combined from various canonical pathways. These models
can be used to represent regulation between cellular functions, which has been
one of the challenges in systems biology (Ma’ayan et al., 2005).
The canonical pathways representing chemical reactions of small molecules
are often referred as metabolic pathways. Proteins associated to these pathways
are typically enzymes catalysing these reactions, or their co-factors (Schilling
et al., 1999; Ouzounis and Karp, 2000). The connections between the proteins
related to subsequent reactions are mediated by reactants, which are often small
molecules with a variety of possible targets (Croft et al., 2011; Kanehisa et al.,
2012).
Signal transduction pathways are canonical pathways representing chains of
reactions related to an extracellular stimuli (Jørgensen and Linding, 2010). These
pathways typically represent regulation of certain biological functions, such as cell
cycle adjustment or cell death. In contrast to the metabolic pathways, signal trans-
duction cascades typically involve protein modifications such as phosphorylations
and ubiquination.
Cancer is famous of its ability to activate cellular processes typically inactive in
its cell type lineage (Cui et al., 2007). Typical examples include the activation of
telomerase, increased motility, and epithelial-mesenchymal transition that makes
epithelial cells more resistant to apoptosis and promotes their invasiveness (Hana-
han and Weinberg, 2011). There is a number of ways cancer cells can change their
behaviour by activating or inactivating the cell’s biological processes (Vandin
et al., 2012). The representation of these mechanisms (such as mutations) at the
level of pathways can be used to reduce the complexity and to better identify
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Figure 3: This canonical pathway represents androgen receptor signalling as described
in WikiPathways (Hanspers et al., 2011). The lower part of the figure illustrates the
interactions between the AR and other proteins modulating its activity. The promoting
factors are on the left and the inhibitors on the right.
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2.3 Background of cancers studied in Publications
Cancer is a disease of malignant cell growth caused by a heterogeneous combination
of defects in the genome (Vogelstein and Kinzler, 2004; Gerlinger et al., 2012).
The disease involves interactions between various kinds of cells within and around
the tumour tissue (Hanahan and Weinberg, 2011; Clevers, 2011). Cancer is among
the few diseases caused by somatic mutations (Vogelstein and Kinzler, 2004). The
parental organ and the tissue from which the primary tumour has arisen has been
the major determinants of the diagnosis, but remaining variation within these
cancer classes causes a demand of more specific diagnostics and treatments (Fritz,
2000; Martini et al., 2011; Gerlinger et al., 2012).
Here, we demonstrate new methodologies to analyse genome-scale data in three
different cancers. The biological heterogeneity of these cancers demonstrates the
general properties of the proposed computational approaches and their possible
applicability to a wider set of research.
2.3.1 Colorectal cancer
Colorectal cancer (CRC) covers the tumours of the colon and rectum (Muzny
et al., 2012). CRC is the third most common cancer in males and the second
most common cancer in females in Finland, with an annual incidence of 1415♂ +
1321♀ (Finnish Cancer Registry, 2012). Environmental factors are the major
cause of CRCs but the individuals’ heredity contributes 20%–30% to the risk
of incidence (Lichtenstein et al., 2000; de la Chapelle, 2004). Some of the
high-penetrance mutations are known to affect genes like APC, MSH2, MSH6,
MLH1, PMS2, AXIN2, POLD1, TGFBR2, SMAD4, BMPR1A and MUTYH.
All these examples, except the last one, have a dominant manifestation, which
means that even one mutated allele is enough to cause a genetic predisposition.
The mutations in MUTYH are typically less penetrative unless both alleles are
affected (Papadopoulos and Lindblom, 1997).
The detection of new recessive mutations is an interesting challenge because the
number of phenotype positive cases is limited and a mutation is likely to explain
only a fraction of them. The conventional statistical tests are not sensitive enough
for this purpose and thus we developed a combined approach of a rule based
detection (sensitivity) of the putative sites and the data integration (specificity)
based pruning of the results (Publication I).
2.3.2 Glioblastoma multiforme
Glioblastoma multiforme is a cancer that originates from the glial cells of the
brain (Riemenschneider et al., 2010) and corresponds to the grade IV astrocy-
toma (Louis et al., 2007). Glioblastoma is typically of somatic origin. The diffuse
growth within the brain tissue prevents a complete surgical removal of the tumour,
and current therapies, such as radiation and chemotherapies, produce only modest
responses. The median survival of the treated patients is roughly a year after
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their initial diagnosis (Weller et al., 2009). Metastases on distant organs are rare
and the deaths are typically caused by the primary tumour.
We focused on GBM in Publication II and Publication III because of the
substantial need of new treatments and because TCGA provided its most com-
prehensive data set for this cancer. The data consisted of measurements of
chromosome copy numbers, SNP genotypes, DNA methylation, expression pro-
files at the level of genes, individual exons, and microRNAs. In addition, clinical
data (age, sex, time of diagnosis, time of death, treatment, etc.) was provided
for the patients in the data set. All these data were used in Publication II.
Publication III is based on the expression and clinical data.
2.3.3 Prostate cancer
Prostate is particularly susceptible to cancer and prostate cancer is the most com-
mon cancer in Finnish males, covering 40% of all cases (Finnish Cancer Registry,
2012). The cancer typically develops at old age and grows slowly without notice-
able symptoms. Consequently, many cases are either not diagnosed or treated
aggressively enough. An active surveillance may be enough for those diagnosed
with a low-risk tumour. For the others, surgery, radiation, and chemotherapies
are the most common options.
Œstrogen receptor like steroid receptors such as androgen receptor (AR)
and glucocorticoid receptor (GR) are nuclear receptors, which, once activated,
translocate from the cytosol to the nucleus and bind to the DNA (Aranda and
Pascual, 2001). Once bound to the DNA, they act as transcription factors of
their target genes (Aranda and Pascual, 2001). Various binding motifs of AR
have been reported (Heemers and Tindall, 2007) but little is known about the
exact DNA targets and the co-factors that are involved in the transcriptional
regulation.
Prostate cancers are typically divided to those responding to deduction of
the AR activating ligands androgen/testosterone/5α-Dihydrotestosterone and to
the castration-resistant prostate cancers (CRPC), that have become refractory
to the aforementioned treatments. CRPC cancer may still rely on AR mediated
transcription, although it is independent of the external activators and thus the
understanding of the functions of AR and its co-factors is important for these
cancers as well.
RelPublication represents a hormone dependent cancer with a particular focus
on the transcriptional regulation and the signalling cascades of the hormone. The
publication describes how the AR response differs in the cells in the presence and
in the absence of FoxA1 co-factor.
2.4 Obtaining data from biodatabases
Biomedical information has been accumulated into scientific articles over the
years, but utilisation of these resources becomes infeasible when dealing with
thousands of genes. For instance, PubMed returns 5738 articles about the function
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of TP53 gene and 61889 articles for the corresponding p53 protein [29.3.2012].
The invocation of these articles alone would be an overwhelming task for any
human. The number of human genes (> 400001) is comparable to the number of
words people learn for a second language (Schmitt, 2008), not to mention that the
nomenclature of them varies in context and time. Fortunately, automated tools
may help with this complexity, and much of the information has been stored into
various databases. The variety of these databases (Galperin and Fernández-Suárez,
2012) itself is a notable issue, but here we will focus on some of the biggest and
the most relevant databases in the context of cancer research. Some databases are
used to store and share original observations and the latest knowledge, whereas
others act as proxies integrating their content. The relationships between the
databases are often complex and the distinction between the primary sources
and the proxies are often mixed. Same biological entities have been labelled
with different identifiers in different databases, thus the mapping between the
namespaces is an integral part of the practical bioinformatics (Huang et al., 2008).
The human reference genome forms the basis of the genome databases such as
Ensembl, NCBI Entrez (Maglott et al., 2007) and UCSC Genome Browser (Rhead
et al., 2010). These databases focus on the functional and structural annotations
of the DNA regions. The databases can be used to fetch information about the
transcripts, CpG-islands, centromeres, transcription factor binding sites, and
SNPs.
Information about biochemical relationships between different compounds
is gathered in various databases (Bader et al., 2006; Jensen et al., 2009). The
term pathway database is often applied to these databases, especially when the
information has been structured into canonical pathways, whereas it is used
less in the context of less organised collections of molecular interactions. The
classical protein-protein interaction databases, such as MINT (Ceol et al., 2010),
IntAct (Kerrien et al., 2007), DIP (Salwinski et al., 2004), BioGRID (Stark
et al., 2011), HPRD (Prasad et al., 2009), STRING (Jensen et al., 2009) and
PINA (Wu et al., 2008), exemplify the latter case by focusing on the physical
interactions between the proteins and protein complexes. On the other extreme,
in the databases such as KEGG (Kanehisa et al., 2012) and WikiPathways (Kelder
et al., 2012) where the canonical pathways are used to organise the data, the
individual reactions are described in the context of these biological models.
Pathway Commons (Cerami et al., 2010) provides a generic proxy for the public
databases with a BioPAX (Demir et al., 2010; Strömbäck and Lambrix, 2005)
interface. The current [8.3.2012] version covers databases such as Reactome (Croft
et al., 2011) and HumanCyc (Romero et al., 2004), which provide metabolic
pathways. Integrated Pathway Resources, Analysis and Visualization System
(IPAVS) provides curated pathway information combined with the information
automatically imported from other pathway databases (Sreenivasaiah et al., 2012).
IPAVS web application enables direct and manual utilisation of the system. Larger
1Ensembl (Flicek et al., 2011) version 66.37 describes: 20563 known protein-coding genes, 536
novel protein-coding genes, 15520 pseudogenes, 11960 RNA genes, and 637 immunoglobulin/T-
cell receptor gene segments.
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and more automated approaches can be established on the basis of database
downloads, which are supported in various formats.
The relationships between native biomolecules of the host organism and drugs
can be represented much like the relationships between the other compounds (Frol-
kis et al., 2010). New experiments and hypotheses can be derived by combining
drug target information with the other pathways (Publication III; Liikanen et al.
(2011)). In these combined pathways, one can interfere with the system via
the administration of the selected compounds. DrugBank is a proxy database
that combines information about medicines and the genome (Knox et al., 2011).
The database provides information regarding to 6711 drugs, some of which are
experimental (5084) or withdrawn (69). DrugBank describes which proteins
are known to interfere with the particular drug and which parts of the protein
sequences are responsible for the interactions. In addition, plenty of information
is provided regarding the biochemical and pharmacological properties of each
compound. KEGG provides another resource of drug targets and biomarkers
affecting the drug responses.
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3 Aims of the studies
Publication I Development of a sensitive method that works with a limited
number of samples and is capable of revealing sites with possible recessive
and CRC relevant mutations. Development of an automated analysis and
visualisation pipeline that can be applied and customised for other SNP
data sets.
Publication II An establishment of a computational framework for the system-
atic analysis of a large and heterogeneous data set. Built-in support for
the documentation, integrity checks, and the simple manipulation of the
analysis were the key requirements for the collaborative platform. We were
interested in applying this framework to TCGA GBM data set in order
to find new survival associated genes and to prepare the data in a more
suitable format for other studies.
Publication III Development of a software infrastructure that would use exist-
ing information to reveal relationships and causalities between the genes of
interest. Automatically generated graphs are produced on demand for the
genome-scale studies so that they can operate on models adjusted for their
data instead of using fragmented models of canonical pathways.
RelPublication Identification of the AR binding sites and the associated co-
factors in human prostate cancer cells. Characterisation of interplay between
AR and FoxA1, and the prognostic value of FoxA1 activity.
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4 Materials and methods
We have used an iterative development process in all projects. An automated
pipeline has been established for each project. This pipeline carries out the com-
plete analysis from the pre-processing of the data to the reporting (Publication III;
Laakso et al. (2011)). Individual steps have been implemented as components,
which we have been able to recycle between the projects (Johnson, 1997). The
exact configuration of the analysis pipeline evolves during the iteration as new
hypotheses and adjustments are made on the basis of the previous results.
4.1 Detection of recessive mutations
The recessive mutations manifest a cancer phenotype in the absence of a dominant
allele. Such conditions typically arise when the same recessive allele has been
inherited from both parents. In this case the homologous chromosomes are
identical for the particular region, which is now called homozygous. One may
have also inherited two different recessive alleles (these individuals are called
compound heterozygotes) or the dominant allele has been lost. The somatic
deletions causing loss of heterozygosity (LOH) have been associated with the
inactivation of various tumour suppressor genes (Huang et al., 1992; Cawkwell
et al., 1994; Beroukhim et al., 2006). In familial predisposition cases we are trying
to measure germline DNA and avoid somatic changes, although these changes
cannot be totally excluded as the sample material has been isolated from blood
(controls) and tumour surrounding tissue (cases).
The resolution of a SNP-microarray is a fraction of the complete sequence,
but we show that the microarrays can be used for the detection of homozygous
regions. First, there has to be enough SNPs in linkage disequilibrium, in other
words, their alleles tend to segregate together. Second, both alleles have to be
common enough so that they provide information about the sample haplotypes.
In fact, the common definition of SNP implies that the frequency of the rare
allele is at least 0.01 at the population level (Mooney, 2005). Once we observe
a long series of such SNPs with homozygous genotypes in a particular sample,
it becomes more likely that the sample has two identical copies of the same
ancestral haplotype (shared identity by descent) than two different haplotypes
with the exact match of the SNP alleles. The homozygous regions are interesting
because we can assume that a (possibly existing) recessively manifested mutation
co-segregates together with the SNP alleles, whereas the same does not hold for
the former case of heterozygous regions unless they are compound heterozygotes.
The detection of putative mutation regions with possible genotype mistakes
resembles the detection at LOHs in the absence of the normal tissue references,
but simple algorithms can be used as there is no need to distinguish between
the homozygous and heterozygous signal strengths (Dutt and Beroukhim (2007);
LaFramboise (2009); Publication I).
Each chromosome is processed separately as the partitioning of the data
improves its computational analysis. The genomic regions that are identical by
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descent (IBD) (Thomas et al., 2008) are considered to be continuous segments
in the context of the human reference genome. The segments are limited by the
meiotic recombination between the homologous chromosomes. Our study focuses
on the autosomes; the sex and the mitochondrial chromosomes were discarded by
the analysis pipeline.
The recessive phenotypes, such as tumour suppressor deactivation mediated
cancer susceptibility, which are harmful for the individual, are rare and conse-
quently the sample material is limited. We identified 50 unrelated patients out of
1044 CRC cases, which were collected during previous studies of DNA replication
errors and microsatellite instability in CRC (Aaltonen et al., 1998; Salovaara et al.,
2000). For these patients the cancer was not explained by the known mutations
and they all had at least one sibling with a CRC diagnosed. The genotyping was
carried out successfully for 42 CRC patients and 50 blood donors using Affymetrix
GeneChip R© Human Mapping 100 K Set and the standard protocol (Affymetrix,
2004). Two patient samples were known to harbour a mutation in MUTYH gene
and they were used as spike-in controls for the evaluation of the hit ranking
scheme.
An ideal comparison between the cases and controls would be based on
haplotypes, which can distinguish between a mutation allele and other possible
alleles present homozygously. However, the resolution of the microarrays we used
and the small number of samples limited our options in that. In Publication I, we
used haplotype estimates only to estimate missing data, but Haplous (Karinen
et al., 2012) extends our methods for the comparisons at the level of haplotypes.
In our case, the distinction between different alleles is made independently for each
SNP by dividing them to the wild type alleles (those with the highest frequencies)
and to the rare variants (the alternative nucleotide supported by the microarray).
The advantage of this frequency based assignment is that it reduces entropy in
the allele sequences and simplifies the visualisation as the wild type alleles (in
upper case) are likely to be followed by wild type alleles (ABCDE versus AbCde).
CRC is a complex disease that can be caused by various different muta-
tions (Kinzler and Vogelstein, 1996). Thus, we expect that only few samples
share a common recessive mutation (Aaltonen et al., 2007). A detection method
that would be able to call 2–5 cases among 42 patient samples and to compare
them against 50 population controls has to be more sensitive than the standard
statistical tests based on the frequency comparisons. Consequently, we formulated
a rule based filter that provides a list of all genomic regions which have enough
(> 1) overlapping homozygous regions in patients and which are rare (none is
observed) among population controls.
A majority of the accepted regions are obviously not related to the CRC sus-
ceptibility, but a ranking scheme was established to highlight the most prominent
candidates. The ranking is based on the score that represents the total length of
the homozygous regions contributing to the region. Longer regions are more likely
to be identical by descent (Thomas et al., 2008). A higher number of samples
with such overlapping regions provides a higher association to the phenotype.
The top scoring regions were subjected to an annotation pipeline that fetched
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the overlapping genes, which were in turn compared against the CRC candidate
genes suggested by the SNPs3D text mining service (Yue et al., 2006) and by
Sjöblom et al. (2006) about frequently mutated genes in breast and colorectal
cancers.
SNPs3D is a database that provides information about the phenotypes associ-
ated with SNPs and genes (Yue et al., 2006). The database consists of modules
providing services such as functional annotations of SNPs and construction of
interaction networks of the query genes. Disease Candidate Gene module is one
part of the database specialised in text mining based mappings between diseases
and genes. The mappings are generated in four steps using the abstracts of the
articles stored in MEDLINE. First, abstracts referring to the name of the disease
are selected. Second, the frequencies of the keywords among the selected abstracts
are compared against their total frequency among the MEDLINE abstracts and
a list of 40 most enriched keywords is formed. Third, a score is calculated for
each gene as a sum of keyword specific affinities. These affinities are products of
the ratios of the disease name and the gene among the abstract containing the
particular keyword. Fourth, genes are ranked based on their scores and reported.
4.2 Data analysis framework
Integrative projects using multiple data types (for example gene expression, DNA
methylation, DNA copy number, genotype data) and databases are challenging
for the management of the data analysis. Each data type may introduce its own
set of quality check, formatting, normalisation, analysis, and reporting steps to
the project, and a complete analysis may consist of hundreds or even thousands
of individual steps (Laakso et al., 2011). We prepared a computational framework
called Anduril that can be used to combine different computer programs on
different environments together and to handle the data flow between them.
Anduril provides its own workflow configuration language (AndurilScript)
that is used to bind outputs of one program, or a component, to the inputs of
the subsequent components. Each component provides an interface describing
its inputs, outputs and the parameters, but the underlying implementation
is language independent. The distribution provides convenience libraries for
Bash, Lua, MATLAB, Perl, Python, R, and Java, but other languages and
stand-alone applications can be used as well. Aggregate components can be
prepared by combining other components together with the AndurilScript. These
constructions, referred as functions, provide recyclable routines that can be used
even across the projects.
All communication between components is mediated by the files produced by
the upstream components and provided to their downstream components. The
workflow engine takes care of the exact locations of the files and communicates
them to the components. The downstream components are launched only after
the completion of their upstream neighbours, which is in contrast to some other
workflow engines like Orange (Curk et al., 2005) and Ergatis (Orvis et al., 2010)
that support message streams between the components. Although sometimes
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slower, the file mediated communication simplifies the language and platform
independent implementation of components, enables recycling of still valid results
between the executions, and provides a well-organised repository of results of
each step of the analysis.
Anduril has been designed for projects which may consist of thousands of
individual component instances. A graphical user interface would be impractical
for such cases, thus a more suitable console based user interface has been chosen
instead. The terminal based user interface simplifies remote access, and a session
can be left open for days depending on the total execution time. The custom
language was established in order to simplify construction and modification of
workflows. The current version of AndurilScript supports inheritable data types,
conditions, loops, nested workflows, arrays, etc. The compile time validation of
the workflow and the re-execution of modified or out-dated results enables the
maintenance of workflows with thousands of steps.
An integrative bioinformatics infrastructure enables large scale studies (Almeida,
2010). Identification of prognostic genes and possible therapeutic targets in GBM
is a challenge where such infrastructures can be applied (Publication II). The Can-
cer Genome Atlas provides a wide set of measurements and clinical information
about 338 (November 2009) GBM patients and their tumours (McLendon et al.,
2008). We used Anduril to establish an analysis pipeline for the DNA copy number,
SNP genotype, gene expression, microRNA, and methylation data. The DNA copy
numbers were estimated from the comparative genomic hybridisation array data,
and the gene expressions were measured using two different microarray platforms.
Affymetrix HU133A provided information at the level of genes, whereas Affymetrix
Human Exon 1.0 platform was capable of detecting differences between the exons.
The information of each data type was merged at the level of genes, which led to
a large matrix of genes and associated results. The final matrix was represented
as a web site (http://csbi.ltdk.helsinki.fi/anduril/tcga-gbm/) for the
simultaneous accession of multiple aspects of the cancer.
The plausibility of the survival association between the result genes was tested
on four (three glioma and an SV40 transformed fetal astrocyte) cell lines. A
total of 11 genes (CDKN2A, FLNC, H19, HIST1H4L, KIAA0040, LTF, NNMT,
POSTN, TAGLN2, TIMP1 ) were selected on the basis of upregulated expression
and the survival association. We tested if the downregulation of these genes
has an impact on the proliferation or apoptotic activity of the cells. A small
interfering RNA (siRNA) silencing was performed with four different siRNAs
against each gene. The proliferation of each cell line was reduced by the MSN
targets, but the responses of the other genes were less consistent or negligible.
4.3 Analysis of AR binding sites
We studied the target genes of AR on a modified LNCaP-1F5 human prostate
cancer cell line that expresses rat GR. The modified cell line was chosen because
we were also interested in the interplay between AR and GR. The DNA binding
responses were measured 2h after a 5a-dihydrotestosterone stimulus and the
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mRNA was collected 24h after the stimulus. Another series of experiments was
carried out after depletion of FoxA1 with small interfering RNA.
The transcriptional responses were analysed from the collected mRNA. Two
replicates were prepared for each condition (before the stimulation, AR response,
FoxA1 depleted cells before the stimulation, and the same cells after the stim-
ulation). Illumina HumanHT-12 v3 Expression BeadChip Kit was prepared at
Biomedicum Functional Genomics core facility and the data files were sent to us
for the data analysis that was implemented in Anduril (Laakso et al., 2011). The
signals of all samples were quantile normalised, and the mapping between the
microarray probes (illumina humanht 12 probe set) and the genes was revised
using Ensembl BioMart. A fold change was calculated for each gene between
the medians of the replicates by dividing the response signal with the preceding
control signal. Genes with a fold change less than 1/1.7 and greater than 1.7
were considered down- and upregulated, respectively. The threshold was selected
empirically so that enough DEG were obtained for the peak assignment and
the downstream analysis but simultaneously avoiding spurious results caused
by the limited number of replicates. No false positives were found during the
validation of the transcriptional changes but only few genes were covered in
details (RelPublication Supplementary Information).
The identification of the transcription factor binding sites and their target genes
was conducted in multiple steps. In the beginning, the short read sequence data
was aligned against the human reference genome using ELAND algorithm (Bentley
et al., 2008). Two mismatching base pairs were allowed within an accepted short
read. Reads that did not align to the reference genome or had multiple alignments
were ignored. The alignments of the accepted reads were used to estimate the
relative abundance of the DNA fragments along the genome. Figure 4 illustrates
the counts of overlapping short read alignments at two selected regions of the
genome.
The sequence alignments were analysed with MACS (Zhang et al., 2008)
algorithm that estimates their local enrichments across the genome. MACS is a
peak calling algorithm that has been designed for the TF ChIP-seq. A variety of
algorithms, which differ in their sensitivity and the widths of the peaks called
exists for the same purpose (Wilbanks and Facciotti, 2010). In addition to MACS,
we also analysed our samples with SPP (Kharchenko et al., 2008), which is an
R package for the ChIP-seq analysis. MACS is relatively stringent in calling
peaks and reports narrow and highly reliable peaks but is likely to miss some
less obvious sites. SPP turned out to be even more conservative, reporting about
1/3 less sites, which is consistent with the FoxA1 observations made in Wilbanks
and Facciotti (2010). The input of the peak calling programs consists of the
aligned short reads of the actual TF ChIP-seq (case) and of those representing
an unspecific antibody (control). An enrichment is called where the case reads
have a considerably higher overlap of reads in comparison to the control set. The
effects of the clonal artefacts produced by the polymerase chain reaction based
amplification of the DNA are reduced by accepting only one read for each unique




Figure 4: Examples of the local enrichments of the aligned ChIP-seq reads under
various conditions. The upper most signal represents FoxA1 binding on FoxA1 depleted
cells (should not be observed if the depletion is efficient), below is the same for the
parental cells followed by a similar pair of AR bindings. A) depletion of FoxA1 brings
AR to the new sites, some of which match well with the previous FoxA1 sites at the
promoter of EVL gene. B) FoxA1 dependent AR sites of LPAR3 are lost after the
depletion.
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enrichments on both of the DNA strands. These sites represented an overall
set of binding sites p and their fold enrichments w against the control samples.
ChIP-seq peaks analysed were determined as overlaps of the MACS (Zhang et al.,
2008) peaks of all ChIP-seq sample replicates. Two replicates were produced for
AR and FoxA1 in parental cells and AR in FoxA1 depleted cells. Four replicates
of FoxA1 BSs were prepared for the FoxA1 depleted cells to compensate the weak
signal and the relaxed peak calling criterion. Having the replicates, we considered
the wider set of MACS peaks more comprehensive and reliable enough, although
the SPP peaks were probably more accurate for the positioning of the binding
site (a single bp coordinate was returned for each peak).
The assignment of the ChIP-seq peaks to their target genes produces a many-
to-many relationship, where each peak may have none or many target genes. We
constructed this mapping by assigning each peak to all genes within the distance
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presented in Ouyang et al. (2009). An arbitrary cut-off of 11 was used to select a
set of genes with a TF association. This cut-off provided a good overlap with
the differentially expressed genes (DEG) while reducing the number of genes
associated. The downstream analysis of the TF BSs was conducted for the sites
that contribute to the scores of the selected genes. The rest of the peaks were
filtered out in the absence of TF associated genes in their proximity.
The possible co-factors of the AR were not well known when we initiated
our study but the ChIP-seq protocol enabled a detailed profiling of the AR
binding sites. The DNA sequences of thousands of binding site peaks were used
to describe the surroundings of the AR bindings in terms of TF binding sequences
of possible co-factors. A more focused analysis was performed by combining the
gene expression data with the BSs and by focusing on the sequences assigned
to DEG. This BS oriented approach reduces the complexity of the traditional
promoter sequences analysis that considers a possibly long upstream sequence
ahead of the genes of interest (D’haeseleer, 2006).
First, the peak sequences were fed to MEME (Bailey et al., 2006) for the
de novo motifs discovery. MEME is an iterative expectation maximisation
(EM) algorithm that collects statistically unlikely but still frequent sequence
motifs (Bailey, 1994; D’haeseleer, 2006). When successful, this approach is
capable of revealing unexpected or unknown binding site sequences that are
enriched in the given set of input sequences, as we will show later in the results
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section. In this context, EM is an optimisation procedure that adjusts the
motif so that the equally long fragments of the input sequences are more likely
generated by the motif than the background probabilities (typically relative
frequencies) of the nucleotides. The motif is represented as an n nucleotides
long position weight matrix of the nucleotide probabilities. In our case, n was
between 6 and 15. The probabilities of the input alignments are used as their
weights when the matrix is revised for the new positional averages and for the
next iteration. The preprocessing of the MEME input involved filtering of the
repetitive sequences (conducted in the Ensembl database) and selection of at
most 500 most reliable peaks. The repeat masking prevents the program from
discovering the spurious patterns representing nucleotide repeats that are of no
interest. The most reliable peaks are selected based on the fold enrichment score
of the corresponding MACS peaks, and the limit of at most 500 peaks is used
to guarantee a reasonable computational time (Hu et al., 2010). Neither the
sequence and alignment qualities nor fold enrichments are considered during the
motif construction. A more recent algorithm called Hybrid Motif Sampler is able
to utilise this information while processing tens of thousands of ChIP-seq peak
sequences (Hu et al., 2010). We have not yet tried the program but consider it
for the future.
Second, known binding motifs were downloaded from JASPAR (Portales-
Casamar et al., 2010) database. These motifs were combined with some other
motifs using a method we prepared based on literature (Wang et al., 2007).
Figure 5 illustrates the generic function that was used to align all motifs against
the peak sequences and against sequences of the same lengths and chromosomes,
but randomised positions. The alignments between the peak and the random
sequences were compared in terms of frequencies of matches; scores above the
threshold (0.9) dependent limit we consider to represent a reasonable match.
The exact limit was calculated for each motif based on the highest (Sh) and the
lowest (Sl) possible alignment score (the scores of the best and the worse possible
sequence match): threshold · (Sh − Sl) + Sl.
4.4 Interpreting new results with the existing informa-
tion
We are using existing knowledge to organise the initially less structured data,
such as BSs and DEG, into forms that are easier to interpret and more suitable
for further predictions. We found fusion pathway models especially suitable
for this purpose since these models are not restricted to the limited scopes of
the canonical pathways (Publication III). The directed edges can be used to
derive causalities that cannot be told from the static input data. The edge types
representing the modes of interactions between the pathway entities are taken
into account during the model construction in order to avoid interactions less
relevant for the observations. Although useful in revealing dependencies and
separating causes from consequences, predicted properties of the overall graph
































Figure 5: The structure of the Anduril workflow that compares alignments of the
selected motifs (motifPool) between the given sequences (seqARnoF-intPeaks) and the
random background (randomRegions). The labels of the nodes represent names of
the component instances and their types. The rounded shapes are files whereas the
rectangular ones represent Anduril components. The output of this workflow is a LATEX
table representing the differences.
The roles of individual genes may be context specific; their actual membership
may have different confidence; and the actual outcome may be determined by a
minor fraction of the participants.
The metabolic pathways have been included in our system, but we have
adjusted the level of abstraction for them. Our focus has been in the genetics,
and thus we replaced the reactions of small molecules with the connections
between the enzymes related to the reactions producing and consuming them. The
mapping logic is partly adapted from the Simple Interaction Format representation
provided by Cerami et al. (2010). Enzymatic activities of the proteins are stored
as Enzyme Commission numbers (Webb et al., 1992) assigned to the encoding
genes, which are annotated with their Ensembl and Entrez identifiers for mutual
compatibility (Philippi and Köhler, 2006).
The protein level relationships, such as phosphorylations, protein-protein inter-
actions, etc., are represented at the level of the encoding genes. This conceptual
simplification prevents us from modelling differences between the differentially
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spliced isoforms and between the different states of the proteins (Philippi and
Köhler, 2006). We chose this approach once we noticed that the available infor-
mation, even if presented as protein identifiers, makes no difference between the
isoforms. Consequently, the use of protein level links produced a trivial expansion
of the current model. All the proteins of the genes were connected to all other
proteins of another gene if there was a relationship between any of these proteins.
The proteins and their UniProt identifiers (The UniProt Consortium, 2012) are
preserved in the database and connected to their encoding genes.
Our fusion pathway construction methods (Publication III) are intended
for the genome-scale studies where little is known about a large set of entities.
For example, we may only know the mutation status of the genes or their
expression status. On the other hand, this information may be available for a
significant portion of the genome. Consequently, our models are more descriptive
than predictive in comparison with kinetic models, which are more detailed
(considering concentrations and reaction rates) and focused on a smaller number
of entities (Ruths et al., 2008). The balancing between conflicting signals, such
as concurrent promotion and inhibition, is solved by including both options with
an undetermined outcome.
Each link between bioentities has a direction and a type, which specifies its
meaning in terms of how the source entity is related to the target entity (for
example, the source gene encodes the target protein or the source drug inhibits the
biological function of the target entity). Undirected relationships, such as protein-
protein interactions, are stored once for both direction. The links may have
weights associated to them but suitable reliability scores are rarely provided by
the source databases, and thus this feature is not used in our analysis. Resources
such as Biomine (Eronen and Toivonen, 2012) and STRING (Jensen et al., 2009)
may be considered for this information in future. Additional key-value pairs can
be attached to the links for more detailed information. The use of these pairs
may depend on the on the link type. Some of the keys have been reserved for
the source databases whereas the values are used for more specific references to
the origin of the link. The information about the origins of the links is useful for
the tracing purposes, but patterns of key-value pairs are also used to restrict the
scope of the queries. For instance, links of certain canonical pathways can be
obtained by referring to the database (key) and by enumerating the pathways
(values) of interest.
It is essential to upgrade database content as new information becomes
available. Some data sources, such as KEGG and TCGA, are highly variable
providing some changes almost each week. We have implemented our data
retrieval algorithms so that they can be executed as often as needed and they
will add previously unobserved items to the database. The removal of expired
entities and connections is more challenging than the insertion of new entries.
This is because one has to compare all previously collected information against
the new information available in order to know what has been left out. Many
database items are referred to various data sources, which means that one should
make sure that none of them is using a resource before removing it. We have
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solved this consistency requirement by establishing an automated and repeatable
construction pipeline that builds the complete installation from the source code.
The structural changes of the database schema and the alterations in the behaviour
of the importing routines can be carried out without transformations to the already
stored data. The complete build cycle of the installation script takes less than a
day.
In Publication I we demonstrated integration between the literature and the
result sets using SNPs3D and an article about frequent mutations in breast and
colorectal cancers (Sjöblom et al., 2006). The same concept has been further
developed to support simultaneous comparisons across dozens of data sources. The
originally used article has been replaced with wider and more recent cancer data
sets like COSMIC, TCGA and Tumorscape (Beroukhim et al., 2010). Each set of
candidate genes and the associated context specific weights are now stored into a
relational database where they are readily associated to the diseases, pathways,
drugs, and other stored concepts. A set of algorithms has been designed that
can be used to compare gene sets against each other, to describe genes with
the supporting evidence, and to provide meta-ranks based on appropriate sets.
For instance, a meta-study about tumour suppressor genes can be conducted by
combining the related candidate sets to a meta-rank that provides the genes most
frequently associated with a chromosomal deletion, mutation or transcriptional
dysregulation with the highest confidence (Partanen, 2012). Having a meta-rank
of study specific averages, produced in seconds, one can tell which results are
most prominent candidates among a local set of results. An example of potential
tumour suppressor genes is shown in Table 1. The original rank is pruned by
excluding the genes that were ranked high based on chromosomal amplifications
in the same tumour data sets as they were frequently deleted. Scores of each
individual study are normalised by sorting them based on their original scores
and by replacing the original scores with a linear rank that comes from one (the
highest score) towards the last item of 1/n. An average of linear ranks is applied
to items with an equal original score and thus having an unspecified order. Zero
is considered for the genes outside of the set as the study provides no evidence
supporting them. The zeros are used in place of missing values because many
gene sets are based on genome-wide studies, which may have actually considered
these genes, although they have not been included to the result set. The measures
of the genes may have been below the study specific thresholds and such genes
would probably score close to zero if included. By expanding the gene sets in this
way, one could leave zeros out when counting the averages for the meta-rank and






















































































































TMPRSS5 0 0.886 0 0 0.89 0.954 0 0.507 0.797 0.448
SYNE1 0.793 0.756 0.712 0 0.853 0 0.784 0 0 0.433
PARK2 0 0 0 0 0.661 0.767 0.809 0.507 0.981 0.414
EBF2 0 0 0 0 0.848 0.998 0.906 0.972 0 0.414
PTEN 0.617 0.394 0.149 0 0.322 0.324 0 0.915 0.958 0.409
RB1 0.612 0 0.147 0 0 0.968 0.995 0.94 0 0.407
CDCA2 0 0 0 0 0.838 0.996 0.842 0.966 0 0.405
GNRH1 0 0 0 0 0.797 0.996 0.842 0.966 0 0.4
KCTD9 0 0 0 0 0.736 0.996 0.842 0.966 0 0.393
FOXO1 0 0 0 0 0.863 0.871 0.978 0.781 0 0.388
CDKN2A 0.686 0.39 0.709 0.997 0.679 0 0 0 0 0.385
TP53 0.837 0.771 0.974 0 0 0 0 0.81 0 0.377
KIT 0.816 0.676 0.903 0 0.983 0 0 0 0 0.375
DOCK5 0 0 0 0 0.512 0.996 0.869 0.972 0 0.372
Table 1: This example of tumour suppressor genes shows genes with the highest mean
scores excluding the genes with frequent amplifications in breast, ovarian, or prostate
cancer or in melanoma. Chromosomal deletions are taken from Tumourscape. Mutation
frequencies have been collected from COSMIC and the gene expression data comes
from our Anduril based TCGA workflow.
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5 Results
All methods described in this dissertation are freely available on Internet. The
documentation and the software downloads can be found from the following sites:
The detector of the recessive mutations (Publication I)
http://www.ltdk.helsinki.fi/sysbio/csb/downloads/CohortComparator/
Anduril workflow engine (Publication II; RelPublication)
http://csbi.ltdk.helsinki.fi/anduril/
Moksiskaan database and the related Anduril extensions (Publication III)
http://csbi.ltdk.helsinki.fi/moksiskaan/
5.1 Analysis of the CRC genotypes
We produced a highly sensitive method that is able to use SNP genotype data to
narrow down the genomic search space for recessive mutations. Four important
optimisations are:
1. selection of the sites that are homozygous;
2. filtering of the sites that are homozygous in the control samples;
3. annotation and property based ranking of the sites;
4. reporting each site at the level of individual homozygous samples.
The great reduction of the search space implies a change of missed mutations.
We performed a probabilistic simulation of the algorithm to see how likely it is
able to detect a mutation for various combinations of mutation frequencies of
cases and controls (Publication I). Based on these simulations it seems that a
mutation region is preserved with a reasonable probability when the probability
of homozygous regions in control samples is low at that site (or they have another
allele). The method is not suitable for the low penetrance phenotypes where a
higher fraction of control samples may carry a mutant genotype.
The algorithm was tested by extending the set of 40 case samples with two
samples having known but different mutations in MUTYH gene. The spike-in
controls were correctly identified with partially overlapping, long, homozygous
regions. The gene annotation based ranking proposed MUTYH site as the fourth
most prominent one, which suggests that only few sequence validations would
have been needed in order to detect these mutations had they been unknown.
The rule based filter produced 1874 genomic sites compliant with the recessive
pattern. We used the shape of the ranking score distribution to estimate its
saturation point, which left the 181 highest scoring regions for further inspection.
A mutation of our interest could have a form of a non-lethal deletion in a
tumour suppressor gene. We assumed that the SNP genotype calls of homozygous
deletions or unexpected alleles would be missing values, and used our method to
identify short sequences of them much like we did for the homozygous regions.
The analysis identified 13 possible sites. Each site had at least two cases with
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sequences of at least three SNPs without a genotype call but no controls with
a sequence of more than one genotype failure. Polymerase chain reaction assay
validation was unable to capture deletions at these sites, suggesting that the
deletions are better captured by the copy number detection methods specially
designed for this purpose (Colella et al., 2007; LaFramboise, 2009).
5.2 Candidate pathways
We developed a methodology and a computational platform, Moksiskaan, for the
rapid construction of fusion pathways for a given set of genes and proteins (Pub-
lication III). A centralised and uniformed database provides a useful resource for
systems biology (Turenne, 2011). We demonstrated the capability of our platform
in detecting crosstalk between Jak-STAT and ErbB signalling pathways (Publica-
tion III) — a detection that was later described also in WikiPathways (pathway
WP437).
The biological databases are not readily compatible with each other and
all details are hard to preserve when merging their content into a unifying
schema (Philippi and Köhler, 2006). For example, the upper model in Figure 6
illustrates the AR signalling pathway (WP138) generated from the Moksiskaan
database. The original topology was represented in Figure 3. Total of 85 out of the
original 90 genes preserved their pathway association after the identity conversion,
but the connectivity was almost lost. In this case, the source database represented
these connections with visualised arrows without a semantic association between
the genes on both ends. The bottom model in Figure 6 represents connections
between the 85 genes belonging to the AR signalling pathway irrespectively of
the canonical pathway that has described it in KEGG, Pathway Commons, or in
WikiPathways.
Candidate pathways can be used to describe how certain biological processes
such as cell motility, cell death, or cell differentiation, growth and proliferation
are reflected by the transcriptional profile. We demonstrated this strategy by
characterising the effects of depletion of HuR protein in the context of ductal
carcinoma (Heinonen et al., 2011). The processes of interest were first expressed
in terms of GO identifiers, which were then mapped to the genes with the
corresponding annotations in Ensembl database. A candidate pathway was
constructed so that DEG with the annotations of interest were used as seeds but
all DEG were used for the status information.
One of the advantages of an integrated biodatabase is that it enables simple
queries across multiple sources of information. Such queries are useful when the
relationships and the roles of some experimentally observed genes or proteins
are not known (Eronen and Toivonen, 2012). For instance in Karhemo et al.
(2012) we had 23 genes encoding cell surface proteins with different abundances in
metastasising cells in contrast to cells producing no metastases to the lungs. The
roles of the genes were first characterised by fetching the downstream target genes,
diseases, biological processes, and the molecular functions. Processes such as cell










































































































Figure 6: The upper pathway represents androgen receptor signalling as stored to the
Moksiskaan database. The majority of the original connectivity (Figure 3) has been
lost during the importing procedure. The lower pathway has been constructed between
the members of the original pathway but the connectivity represent the union of the
pathways from KEGG, Pathway Commons, and WikiPathways. The ratio of input and
output connections determines the shades of red used for the genes. Red genes have
only downstream neighbours whereas the white ones have none.
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by the proteins (regulation terms in GO). Next, the relationships between the
original genes and the other genes were investigated by retrieving the other genes
connected to them and by establishing all the direct connections between the
resulting genes. The initial graph was pruned by removing edges with a low
Spearman’s rank correlation in the TCGA breast cancer expression data and by
excluding the genes without neighbours. In the final graph, the original edges
were restored between the remaining genes.
5.3 Interplay between AR and FoxA1
The interplay between FoxA1 and AR appeared pivotal once we received the
first results regarding AR BSs. We had executed the motif enrichment pipeline
(Figure 5) and FoxA1 was at the top of the list. The co-operation of AR and FoxA1
(also known as hepatocyte nuclear factor 3, alpha) was previously described in
the context of breast and prostate cancer (Gao et al., 2003; Makkonen et al.,
2008; Hurtado et al., 2010). The enrichment of the FoxA1 BS motif suggested
that the interplay of the TFs is not limited to few individual sites but represents
a common pattern worth genome-scale experiments.
The coverage of the AR binding sites was estimated by sampling random
subsets of the aligned reads and by running the MACS peak calling algorithm
for them. The assumption is that the peak set and the number of peaks would
not change much once there are enough reads to give a reasonable cover for all
binding sites. Total of 20 iterations of sampling and peak calling were performed
for two AR replicates for seven different ratios of sampling coverage. The overlap
of peaks between the sample pair was also calculated for each iteration as we
focused on these overlaps in the actual study, and because it illustrated the
similarities between the peak sets. Ideally, if the binding sites would be the same
in both replicates, and the samples would provide a perfect coverage, then these
overlaps should be almost identical to both replicates. The actual numbers of
peaks represented in Figure 7 show little sign of saturation, and thus we believe
that we have not reached the complete set of the existing binding sites yet.
An interesting sequence enrichment that was present in parental cells but
not in FoxA1 depleted cells was found from the AR binding site sequences. The
sequence motif resembled the AR-motif tail followed by another AR-motif tail
or the beginning of the FoxA1-motif. A similar joint AR-FoxA1-motif was also
discovered in an independent study of AR and FoxA1 silencing (Wang et al.,
2011). The close proximity of the half sites and the absence of the canonical
motif suggests formation of a protein complex, especially because AR and FoxA1
are known to interact with each other (Gao et al., 2003) — a fact that we were
able to pinpoint from the Moksiskaan database. The annotation of the protein-
protein interaction between FOXA1 and AR told that the evidence was obtained
from PINA, that had collected it from Human Protein Reference Database, that
pointed to Gao et al. (2003) via PubMed.
Our AR and FoxA1 study demonstrates how large projects can be handled
with Anduril. The final form of the data analysis workflow included more than
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Figure 7: The number of observed peaks in MACS grows as a function of the input
sequences. The circles and triangles represent peaks from two different AR replicates,
and the crosses represent their overlap. The sampling level tells the ratio of reads
randomly selected from the total number of reads sequenced. The lines have been
drawn between the medians of the peak counts.
1500 input files and component calls, which were all maintained as a single Anduril
process (Laakso et al., 2011). The execution time of this process is roughly two
days when at most 12 simultaneous threads are used on a multi-core server. Most
of the time is spent on the de novo motif discoveries. The workflow includes
characterisation of 58 sets of BSs representing various intersections and overlaps
between the BS sets and the expression data, which illustrates the usefulness
of the code recycling provided in Anduril. The results of each 53 analyses are
reported in the Section 12 of Laakso et al. (2011).
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6 Discussion
The use of a component-based workflow engine enables the repeatable analysis of
large data sets and helps the management of complex analyses with thousands
of steps. The repeatability and the flexibility of these analyses becomes even
more important in the future as new information and tools become available, and
some of the current approaches shall be replaced. The quick adaptation to the
enhancements in the field will be an advantage in cancer research and it enables
smooth improvement of the results. An iterative approach may be applied to
research projects consisting of an input data, analysis of that data, and reporting
of the results. In that approach, the analysis is revised on the basis of new
relevant data and the methodological progress in the field. An automated system
may be used to upgrade the results and to compare the changes. A standard
interface can be used to publish the latest results for the other projects so that
they can revise their analyses accordingly. Having such an interlinked network
of actively maintained research projects is likely to accelerate responses to new
ideas and observations. The repetition of the same tasks under various conditions
aids the identification of possible flaws that can be fixed and optimised. In the
context of recycled components and interlinked analyses, the improvements may
help a wide community.
One of the challenges in reproducing the work conducted elsewhere is the
lack of detailed descriptions of all affecting parameters and approaches used in
the original work. For this reason, electronic supplementary materials about
the analysis are recommended for the genomic publications (Shi et al., 2010).
Anduril is capable of describing the complete workflow in a detailed manner that
is suitable for the article supplementary material, thus the recommendation has
been followed in various publications (Publication II; Publication III; Heinonen
et al. (2011); Laakso et al. (2011); Liikanen et al. (2011); Karhemo et al. (2012)).
The establishment of an integrative systems biology infrastructure is a notable
effort that could benefit a wide community if shared openly and documented
properly (Philippi and Köhler, 2006). We have followed common standards in our
application programming interfaces and provided an extensive set of documenta-
tion, most of which is automatically generated and kept in synchronisation with
the project. Although technically shareable and open, Moksiskaan database have
been kept mainly at local installations because of the issues related to the licensing
of the source databases. The more external code libraries and resources are inte-
grated, the more complicated the copyright and sharing policies become (Philippi
and Köhler, 2006). Data sets may be provided for academic projects but the
copyright restrictions prevent researchers from establishing secondary on-line
services on the basis of them. Original measurements are often published together
with the gene expression microarray related articles, and funding agencies such
EU and some governments are encouraging researchers to share the data they
have produced. Similar strategy could be applied to the software and databases
produced by the scientific labs by promoting licenses that allow their use in other
services. A simple licensing scheme would be a great leap towards large scale
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data integration systems, such as IPAVS, in contrast to the currently fragmented
nature of the biodatabases.
The quality of the data in an integrative system is heavily dependent on that
of the original sources. A joint set of information is vulnerable of false positives if
an incorrect piece of information is preserved by at least one of the sources. For
this purpose, special collections of curated corrections can be beneficial. These
collections would represent negative evidence i.e. what should not exist in the
database so that it can be distinguished from the missing information. The
database schema of Moksiskaan supports curation data sets providing counter
evidence regarding the bioentities and the relationships between them. In future,
we may use this functionality to publish some curation data sets. Some of the
flaws of the source databases can be captured during the data integration as they
may violate integrity constraints of the system or cause unexpected situations
when combined with the other sources of information. Although an integrative
database enables parallel profiling of many data sources, it may introduce its own
errors when interpreting and converting the source information to the local data
structures (Moussouni et al., 2007). For the curation purposes, the traceability
of the information is essential so that the users of the database can find the
original sources of evidence, and the possible mistakes can be corrected where
they were introduced. Even the curated databases may have a significant portion
of mistakes and missing information (Cusick et al., 2008), thus periodic upgrades
can be seen as an integral part of the bioinformatics.
The analysis of homozygous mutations was an example of a study with a
relatively small number of samples. The conditions are even more challenging
in the analysis of individual tumours required for personalised medicine. We
have touched on this field by characterising enzymatic alterations in glioblastoma
patients with Moksiskaan tools (Louhimo et al., 2012). In that study, we show
how to use large sets of other patients as background knowledge to be able to tell
the important alterations from the less interesting ones. The use of generic and
adjustable analysis tools provides cost effective processing of individual patient
data. Still, novel methods and a multitude of samples are needed in order to
interpret the variants that are not part of the reference genome. At an individual
level these non-alignable sequences may constitute a reasonable part (∼9%) of
the genome (Chen et al., 2012). Ultimately, the measurements of each patient
are analysed using his/her own, automatically annotated, genome as a reference.
Prediction of patient survival based on the genome-scale measurements of
the tumour is an interesting challenge for future research. We are planning to
use Moksiskaan pathways for these prognostic purposes. We postulate that a
predictor, once accurate enough, could infer therapeutic targets most optimal
for increasing survival. The advantage of an in silico model is that the effects
of various perturbations can be predicted before applying them to the patient.
We can simulate the effects of all known drugs against the patient model and
calculate their effects on survival estimates. The resulting information may help
when comparing risks and possible therapeutic effects associated to the treatment
of a cancer patient.
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